262 related articles for article (PubMed ID: 10958309)
1. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?
Fatourechi V; Hay ID; Mullan BP; Wiseman GA; Eghbali-Fatourechi GZ; Thorson LM; Gorman CA
Thyroid; 2000 Jul; 10(7):573-7. PubMed ID: 10958309
[TBL] [Abstract][Full Text] [Related]
2. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
3. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
4. Metastatic follicular carcinoma of the thyroid: reappearance of radioiodine uptake.
Oyen WJ; Mudde AH; van den Broek WJ; Corstens FH
J Nucl Med; 1995 Apr; 36(4):613-5. PubMed ID: 7699452
[TBL] [Abstract][Full Text] [Related]
5. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases.
Yaakob W; Gordon L; Spicer KM; Nitke SJ
J Nucl Med Technol; 1999 Dec; 27(4):279-81. PubMed ID: 10646545
[TBL] [Abstract][Full Text] [Related]
8. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
[TBL] [Abstract][Full Text] [Related]
9. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
10. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma.
Nakada K; Katoh C; Kanegae K; Tsukamoto E; Shiga T; Mochizuki T; Itoh K; Tamaki N
J Nucl Med; 1998 May; 39(5):807-10. PubMed ID: 9591580
[TBL] [Abstract][Full Text] [Related]
11. [PET-FDG in thyroid cancer with high thyroglobulin levels and negative 131-I scan. A case report].
Ortega F; Maldonado A; Marañes P; Montz R; Pérez-Castejón MJ; Melgarejo M; Ruiz JA; Carreras JL
Rev Esp Med Nucl; 1999; 18(1):50-4. PubMed ID: 10074219
[TBL] [Abstract][Full Text] [Related]
12. [Results of radioiodine therapy in 47 patients with distant metastases of differentiated thyroid carcinoma].
Miyamoto S; Kasagi K; Endo K; Iida Y; Hidaka A; Hatabu H; Konishi J
Nihon Igaku Hoshasen Gakkai Zasshi; 1991 Jul; 51(7):810-21. PubMed ID: 1891347
[TBL] [Abstract][Full Text] [Related]
13. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
14. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation.
Alam MS; Kasagi K; Misaki T; Miyamoto S; Iwata M; Iida Y; Konishi J
Thyroid; 1998 Dec; 8(12):1091-100. PubMed ID: 9920363
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
Durante C; Haddy N; Baudin E; Leboulleux S; Hartl D; Travagli JP; Caillou B; Ricard M; Lumbroso JD; De Vathaire F; Schlumberger M
J Clin Endocrinol Metab; 2006 Aug; 91(8):2892-9. PubMed ID: 16684830
[TBL] [Abstract][Full Text] [Related]
17. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
18. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
[TBL] [Abstract][Full Text] [Related]
19. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
[TBL] [Abstract][Full Text] [Related]
20. Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy.
Kalender E; Zeki Celen Y; Elboga U; Deniz Demir H; Yilmaz M
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):328-31. PubMed ID: 23084016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]